The new selective I(Ks)-blocking agent HMR 1556 restores sinus rhythm and prevents heart failure in pigs with persistent atrial fibrillation

Basic Research in Cardiology
Alexander BauerWolfgang Schoels


Antiarrhythmic drugs for treatment of atrial fibrillation in patients with heart failure are limited by proarrhythmia and low efficacy. Experimental studies indicate that the pure I(Ks) blocking agents chromanol 293b and HMR 1556 prolong repolarization more markedly at fast than at slow heart rates and during beta-adrenergic stimulation. These properties may overcome some of the above quoted limitations. Ten domestic swine underwent pacemaker implantation (PM) and atrial burst pacing to induce persistent AF. Four days after onset of persistent AF, pigs were randomized to HMR 1556 (30 mg/kg, p.o., 10 days) or placebo. All animals receiving HMR 1556 converted to SR (5.2 +/- 1.9 days), whereas placebo pigs remained in AF. Pigs treated with placebo developed high ventricular rates (297 +/- 5 bpm) and severe heart failure, whereas pigs treated with HMR 1556 remained hemodynamically stable. Left ventricular ejection fraction on the day of euthanization was significantly lower in the placebo compared to the HMR 1556 group (30 +/- 4% vs. 69 +/- 5%, p < 0.005). Similar results were seen with epinephrine levels (placebo 1563 +/- 193 pmol/l vs. HMR 613 +/-196 pmol/l, p < 0.05). Right atrial monophasic action potentials were significantly ...Continue Reading


Sep 1, 1989·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·N B SchillerS Feinstein
Nov 14, 1997·The American Journal of Cardiology·S H Hohnloser
Feb 17, 2001·American Journal of Physiology. Heart and Circulatory Physiology·W HanS Nattel
Nov 2, 2001·Journal of Medicinal Chemistry·U GerlachR Greger
Feb 23, 2002·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·T Szili-TorokL J Jordaens
Mar 28, 2002·Pacing and Clinical Electrophysiology : PACE·Antonio CastroMassimo Santini
Sep 21, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Bente BrendorpLars Køber
Dec 25, 2002·Journal of Cardiovascular Pharmacology·George P ThomasCharles Antzelevitch
Mar 20, 2003·Naunyn-Schmiedeberg's Archives of Pharmacology·Ralph F BoschVolker Kühlkamp
Sep 3, 2003·Journal of Cardiovascular Electrophysiology·Maurits C E F Wijffels, Harry J G M Crijns
Nov 14, 2003·Cardiovascular Research·Klaus J WirthMarkus Bleich
Jan 15, 2004·Pacing and Clinical Electrophysiology : PACE·Eija KettunenLauri Toivonen
Mar 10, 2004·Journal of Cardiovascular Electrophysiology·Peter R KoweyDusan Z Kocovic

❮ Previous
Next ❯


Dec 2, 2009·Nature Reviews. Drug Discovery·Heike WulffLuis A Pardo
Feb 22, 2011·Pharmacology & Therapeutics·A J WorkmanA C Rankin
Apr 19, 2007·Physics in Medicine and Biology·Janine BeckerNina Petoussi-Henss
Mar 22, 2019·Nature Reviews. Cardiology·Sebastian ClaussStefan Kääb
May 29, 2021·RSC Medicinal Chemistry·Matteo BorginiPeter Wipf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.